期刊文献+

马尼地平缓释片的制备及释药机制考察 被引量:3

Preparation and the release mechanism of sustained release tablets of manidipine
原文传递
导出
摘要 目的:研制马尼地平缓释片,并考察其释药机制。方法:将制备的马尼地平固体分散体及乳糖、聚乙二醇、甲基纤维素分别过80目筛,按处方量称取,按等量递增原则于乳钵中充分混匀,干法直接压片即得。结果:马尼地平缓释片的处方组成为HPMC 60RT8000 40 mg,乳糖40 mg,聚乙二醇6000(PEG6000)40 mg,甲基纤维素(MC)80 mg。结论:该缓释片在8 h内呈现良好的零级释放特征,释放机制为骨架溶蚀机制;该缓释片在24 h内药物的释放更符合Higuchi方程,释放机制为非Fick扩散。 Objective: To prepare manidipine sustained-release tablets and to investigate the release mechanism.Methods: The formulations of manidipine sustained release tablets as well as HPMC,MC,lactose and PEG 6000 were sieved by 80 meshes.The release of manidipine from the sustained-release tablets was observed.Results: The composition of manidipine sustained-release tablet was HPMC 60RT8000 40 mg,lactose 40 mg,PEG6000 40mg and MC 80 mg.The release behavior of the tablets followed zero-order kinetic in 0 to 8 h,and it was properly characterized by the erosion mechanism.Conclusion: The release behavior of the tablets follows Higuchi kinetic in 0 to 24 h,and it is properly characterized by the non-Fick mechanism.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第2期177-179,192,共4页 Chinese Journal of New Drugs
关键词 马尼地平 缓释片 释放度 固体分散体 manidipine sustained-release tablets release rate solid dispersion
  • 相关文献

参考文献3

二级参考文献21

  • 1[1]DHEIN S, SALAMEH A, BERKELS R, et al. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide[J]. Drugs, 1999, 58(3):397-404.
  • 2[2]Anon. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure[J]. Arch Intern Med, 1997, 157(21):2413-2446.
  • 3[3]LUSCHER TF, COSENTINO F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal[J]. Drugs, 1998, 55(4):509-517.
  • 4[4]OKABE K, TERADA K, KITAMURA K, et al. Selective and long-lasting inhibitory action of the dihydropyridine derivative, CV-4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery[J]. J Pharmacol Exp Ther, 1987, 243(2):703-710.
  • 5[5]CHEER SM, MCCLELLAN K. Manidipine: a review of its use in hypertension[J]. Drugs, 2001, 61(12):1777-1799.
  • 6[6]PFAFFENDORF M, MATHY MJ, van ZWIETEN PA. Effects of manidipine and other calcium antagonists on rat renal arcuate arteries[J]. Am Heart J, 1993, 125(2 Pt 2): 571-577.
  • 7[7]FOGARI R, ZOPPI A, MUGELLINI A, et al. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives[J]. Cardiovasc Drugs Ther, 1999, 13(3):243-248.
  • 8[8]MANCIA G, OMBONI S, AGABITI-ROSEI E, et al. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients[J]. J Cardiovas Pharmacol, 2000, 35(6):926-931.
  • 9[9]HASE MI, HASE O, IGAWA S, et al. Reduction of left ventricular mass by manidipine hydrochloride[J]. Am J Hypertens, 1998, 11(4 Pt 2):81A.
  • 10[10]TAKABATAKE T, USHIOGI Y, ISE T, et al. Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats[J]. Am Heart J, 1993, 125(2 Pt 2):578-581.

共引文献22

同被引文献19

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部